Subscribe to Search results

RHSC annual return showed 123,998 units of commercial concentrate was used for haemophilia treatment.

Published on:

RHSC annual return showed 354,276 units of commercial concentrate was used for haemophilia treatment.

Published on:

RHSC annual return showed 682,732 units of commercial concentrate was used for haemophilia treatment.

Published on:

RHSC annual return showed 629,697 units of commercial concentrate was used for haemophilia treatment.

Published on:

RHSC annual return showed 485,880 units of commercial concentrate was used for haemophilia treatment.

Published on:

RHSC annual return showed 36,850 units of commercial concentrate was used for haemophilia treatment.

Published on:

RHSC annual return showed 5,460 units of commercial concentrate was used for haemophilia treatment.

Published on:

Dr Willoughby did not realise that commercial Factor VIII concentrates were exposing patients to the risk of viral infections until around 1983.

Published on:

Professor Ian Hann stated that 21 children at the RHSC were infected with HIV relatively early in the HIV crisis, "probably as a result of the widespread use of commercial product."

Published on:

Dr Geoffrey Tovey published a statement regarding the introduction of heat-treated concentrates into the Bristol Haemophilia Centre. His policy was to use NHS products in preference to commercial products and where there was a shortfall of NHS products, priority was given to children and adults known to be hepatitis and HIV negative.

Published on:

Dr Geoffrey Scott complained to Dr Geoffrey Tovey about the insolubility of the Elstree Factor 8 concentrate which meant it could no longer be used for home treatment and therefore more commercial Factor VIII would need to be purchased.

Published on:

In her written statement to the Inquiry, Dr Helena Daly stated that the Bristol Royal Infirmary instituted home therapy for children with severe haemophilia from the age of about four. Cryoprecipitate was seen as impractical for home therapy.

Published on:

Dr Geoffrey Scott wrote to a patient and his wife about another patient attending the Bristol Haemophilia Centre who recently died of AIDS and described the risk of contracting the disease by using imported blood products as extremely small.

Published on:

There were close links between the adult and paediatric treatment in Sheffield Children's Hospital, as well as a close relationship with the regional blood transfusion centre in Sheffield.

Published on:

Dr Lilleyman preferred to use cryoprecipitate for the treatment of children as it only exposed patients to a very small number of UK donors and therefore reduced the risk of viral transmission.

Published on:

It was the view at the Sheffield Children's' Hospital that cryoprecipitate was a safer blood product than factor concentrate.

Published on:

Cryoprecipitate remained in significant use at the Sheffield Childrens' Hospital, although concentrates (both NHS and commercial - but with increasing use of NHS over commercial) were also used. Annual Returns for Sheffield Children's Hospital Haemophilia suggest that cryoprecipitate was used for hospital treatment and that NHS concentrate was used for home treatment.

Published on:

Cryoprecipitate remained in significant use at the Sheffield Childrens' Hospital, although concentrates (both NHS and commercial - but with increasing use of NHS over commercial) were also used.

Published on:

Sheffield Children's Hospital used both cryoprecipitate and NHS concentrates. A small amount of Autoplex was used for the treatment of patients with inhibitors.

Published on:

Sheffield Children's Hospital mainly used cryoprecipitate and NHS Factor 8, with a small amount of Factorate. Autoplex was used for the treatment of patients with inhibitors.

Published on: